insulin and tlr4 inhibitor improve motor impairments in a rat model of parkinson’s disease

Background: insulin resistance is an important pathological hallmark of parkinson’s disease (pd). proinflammatory cytokines during neuroinflammation decrease insulin sensitivity by suppressing insulin signaling elements. toll-like receptor 4 (tlr4), the main receptor involved in neuroinflammation, is also associated with the pathogenesis of pd.objectives: the present study evaluated the effect of insulin, an insulin receptor antagonist, and a tlr4 inhibitor on behavioral deficits and insulin resistance induced by 6-hydroxydopamine (6-ohda). methods: male wistar rats were divided into nine groups: (1) sham (normal saline [ns] in the medial forebrain bundle [mfb]); (2) 6-ohda (20 µg in the mfb); (3) 6-ohda + ns; (4) 6-ohda + dimethyl sulfoxide (dmso); (5) 6-ohda + insulin (2.5 iu/day, intracerebroventricular ([icv]); (6) 6-ohda + insulin (5 iu/day, intranasal [in]); (7) 6-ohda + insulin receptor antagonist (s961; 6.5 nm/kg, icv); (8) 6-ohda + tlr4 inhibitor (tak242; 0.01 µg/rat, icv); (9) 6-ohda + insulin + tlr4 inhibitor. all treatments were administered for seven consecutive days. motor performance was evaluated using apomorphine-induced rotation and cylinder tests. gene expression and protein levels of α-synuclein, tlr4, insulin receptor substrate (irs) 1, irs2, and glycogen synthase kinase 3β (gsk3β) were measured by real-time pcr and western blotting, respectively, in the striatum. results: insulin, alone and with tak242, improved motor deficits induced by 6-ohda. administration of the insulin receptor antagonist had no effect on motor deficits. the increased expression of α-synuclein and tlr4 following 6-ohda was attenuated by insulin and tak242. gsk3β levels, both mrna and protein, were significantly increased by 6-ohda and attenuated with insulin and tak242. conclusions: the findings suggest that 6-ohda induces neurodegeneration via activation of tlr4 and gsk3β, indicating insulin resistance, and that insulin can improve these impairments. moreover, tlr4 inhibition prevents insulin signaling dysfunction and improves behavioral and molecular impairments, highlighting the critical role of tlr4 in the development of insulin resistance in pd pathology.